Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Symptomatic cardiotoxicity associated with 5-fluorouracil

C C Meyer1, K A Calis, L B Burke

  • 1Drug Information Center, Division of Pharmacy Practice, University of Missouri-Kansas City, USA.

Pharmacotherapy
|July 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of metformin on energy intake and satiety in obese children.

Diabetes, obesity & metabolism·2014
Same author

A clinical research integration special program (CRISP) for young women with primary ovarian insufficiency.

Panminerva medica·2014
Same author

The paradox of scientific excellence and the search for productivity in pharmaceutical research and development.

Clinical pharmacology and therapeutics·2014
Same author

A comparison of a T1 weighted 3D gradient-echo sequence with three different parallel imaging reduction factors, breath hold and free breathing, using a 32 channel coil at 1.5 T. A preliminary study.

Radiologia·2013
Same author

The patient-reported outcome (PRO) consortium: filling measurement gaps for PRO end points to support labeling claims.

Clinical pharmacology and therapeutics·2011
Same author

Improving productivity with model-based drug development: an enterprise perspective.

Clinical pharmacology and therapeutics·2010

Continuous 5-fluorouracil (5-FU) infusions can cause cardiotoxicity, especially in patients with prior heart disease. Close monitoring is crucial for these individuals during 5-FU treatment.

Area of Science:

  • Oncology
  • Cardiology
  • Pharmacology

Background:

  • 5-fluorouracil (5-FU) is a common chemotherapy agent.
  • Cardiotoxicity is a known, albeit infrequent, side effect of 5-FU.
  • Risk factors for 5-FU-associated cardiotoxicity require further elucidation.

Purpose of the Study:

  • To determine the incidence of symptomatic cardiotoxicity in patients receiving continuous 5-FU infusions.
  • To identify patient-specific risk factors associated with 5-FU-induced cardiotoxicity.

Main Methods:

  • Prospective cohort study involving 483 patients across 35 hospitals with oncology units.
  • Patients received continuous infusions of 5-FU and were monitored for cardiotoxic events.
  • Univariate analysis was used to identify risk factors.

Related Experiment Videos

Main Results:

  • A total of 9 (1.9%) cardiotoxic events were observed.
  • Cardiotoxicity incidence was higher in patients receiving their first 5-FU course (3.35%).
  • Elevated risks were associated with pre-existing cardiac disease, calcium channel blockers, nitrates, and concomitant etoposide use.

Conclusions:

  • Patients with pre-existing cardiac conditions are at a significantly higher risk of 5-FU-associated cardiotoxicity.
  • Close monitoring and frequent vital sign assessment are recommended for high-risk patients.
  • Further reporting is needed to identify additional risk factors for 5-FU cardiotoxicity.